CoChat
Sign Up
Cited by 260

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis

Zhang, Zhuochao, Li, Xiao, Sun, Wei, Yue, Shuqiang, Yang, Jingyue, Li, Junjie, Ma, Ben, Wang, Jianlin, Yang, Xisheng, Pu, Meng, Ruan, Bai, Zhao, Ge, Huang, Qike, Wang, Lin, Tao, Kaishan, Dou, Kefeng·2017·Cancer Letters
DOI 10.1016/j.canlet.2017.03.004
Open this paper in CoChat — free account

Abstract

Cancer-associated fibroblasts (CAFs) play a pivotal role in regulating tumour progression. Therefore, understanding how CAFs communicate with hepatocellular carcinoma (HCC) is crucial for HCC therapy. Recently, exosomes have been considered an important "messenger" between cells. In this study, we performed microRNA (miRNA) sequencing of exosomes derived from CAFs and corresponding para-cancer fibroblasts (PAFs) of HCC patients. We found a significant reduction in the miR-320a level in CAF-derived exosomes. Using exogenous miRNAs, we demonstrated that stromal cells could transfer miRNA to HCC cells. In vitro and in vivo studies further revealed that miR-320a could function as an antitumour miRNA by binding to its direct downstream target PBX3 to suppress HCC cell proliferation, migration and metastasis. The miR-320a-PBX3 pathway inhibited tumour progression by suppressing the activation of the MAPK pathway, which could induce the epithelial-mesenchymal transition and upregulate cyclin-dependent kinase 2 (CDK2) and MMP2 expression to promote cell proliferation and metastasis. In xenograft experiments involving CAFs mixed with MHCC97-H cells, miR-320a overexpression in CAFs could inhibit tumourigenesis. Therefore, these data suggest that CAF-mediated HCC tumour progression is partially related to the loss of antitumour miR-320a in the exosomes of CAFs and that promoting the transfer of stromal cell-derived miR-320a might be a potential treatment option to overcome HCC progressi…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2017.03.004

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 35

  1. Forner, 2012, Hepatocellular carcinoma, Lancet, 379, 1245, 10.1016/S0140-6736(11)61347-0 · DOI
  2. Tlsty, 2006, Tumor stroma and regulation of cancer development, Annu. Rev. Pathol., 1, 119, 10.1146/annurev.pathol.1.110304.100224 · DOI
  3. Dakhova, 2009, Global gene expression analysis of reactive stroma in prostate cancer, Clin. Cancer Res., 15, 3979, 10.1158/1078-0432.CCR-08-1899 · DOI
  4. Kuperwasser, 2004, Reconstruction of functionally normal and malignant human breast tissues in mice, Proc. Natl. Acad. Sci. U. S. A., 101, 4966, 10.1073/pnas.0401064101 · DOI
  5. Schor, 1986, Occurrence of a fetal fibroblast phenotype in familial breast cancer, Int. J. Cancer, 37, 831, 10.1002/ijc.2910370606 · DOI
  6. Cocucci, 2009, Shedding microvesicles: artefacts no more, Trends Cell Biol., 19, 43, 10.1016/j.tcb.2008.11.003 · DOI · Paper page
  7. Haga, 2015, Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth, J. Extracell. Vesicles, 4, 24900, 10.3402/jev.v4.24900 · DOI
  8. Li, 2016, Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype, Cancer Res., 76, 1770, 10.1158/0008-5472.CAN-15-1625 · DOI
  9. Au Yeung, 2016, Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1, Nat. Commun., 7, 11150, 10.1038/ncomms11150 · DOI
  10. Aucher, 2013, MicroRNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation, J. Immunol., 191, 6250, 10.4049/jimmunol.1301728 · DOI · Paper page
  11. Challagundla, 2015, Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy, J. Natl. Cancer Inst., 107, 10.1093/jnci/djv135 · DOI
  12. Bovy, 2015, Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer, Oncotarget, 6, 10253, 10.18632/oncotarget.3520 · DOI · Paper page
  13. Desrochers, 2016, Extracellular vesicles: satellites of information transfer in cancer and stem cell biology, Dev. Cell, 37, 301, 10.1016/j.devcel.2016.04.019 · DOI
  14. Chou, 2012, MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment, Cancer Discov., 2, 1078, 10.1158/2159-8290.CD-12-0465 · DOI
  15. Zhao, 2012, MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer, Int. J. Biochem. Cell Biol., 44, 2051, 10.1016/j.biocel.2012.08.005 · DOI
  16. Junttila, 2013, Influence of tumour micro-environment heterogeneity on therapeutic response, Nature, 501, 346, 10.1038/nature12626 · DOI · Paper page
  17. Luo, 2016, Tumor microenvironment: the culprit for ovarian cancer metastasis?,, Cancer Lett., 377, 174, 10.1016/j.canlet.2016.04.038 · DOI
  18. Mueller, 2004, Friends or foes – bipolar effects of the tumour stroma in cancer, Nat. Rev. Cancer, 4, 839, 10.1038/nrc1477 · DOI
  19. Albrengues, 2014, LIF mediates proinvasive activation of stromal fibroblasts in cancer, Cell Rep., 7, 1664, 10.1016/j.celrep.2014.04.036 · DOI
  20. Sternlicht, 1999, The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis,, Cell, 98, 137, 10.1016/S0092-8674(00)81009-0 · DOI
  21. Boire, 2005, PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells, Cell, 120, 303, 10.1016/j.cell.2004.12.018 · DOI
  22. Silzle, 2004, The fibroblast: sentinel cell and local immune modulator in tumor tissue,, Int. J. Cancer, 108, 173, 10.1002/ijc.11542 · DOI
  23. Tkach, 2016, Communication by extracellular vesicles: where we are and where we need to go, Cell, 164, 1226, 10.1016/j.cell.2016.01.043 · DOI · Paper page
  24. Vader, 2014, Extracellular vesicles: emerging targets for cancer therapy, Trends Mol. Med., 20, 385, 10.1016/j.molmed.2014.03.002 · DOI
  25. Ohno, 2013, Roles of exosomes and microvesicles in disease pathogenesis, Adv. Drug Deliv. Rev., 65, 398, 10.1016/j.addr.2012.07.019 · DOI
  26. Tang, 2015, Exosomes: emerging biomarkers and targets for ovarian cancer, Cancer Lett., 367, 26, 10.1016/j.canlet.2015.07.014 · DOI
  27. Lemoinne, 2014, The emerging roles of microvesicles in liver diseases,, Nat. Rev. Gastroenterol. Hepatol., 11, 350, 10.1038/nrgastro.2014.7 · DOI
  28. Zhao, 2014, miR-320a suppresses colorectal cancer progression by targeting Rac1, Carcinogenesis, 35, 886, 10.1093/carcin/bgt378 · DOI
  29. Wang, 2016, MiR-320a inhibits gastric carcinoma by targeting activity in the FoxM1-P27KIP1 axis, Oncotarget, 7, 29275, 10.18632/oncotarget.8676 · DOI
  30. Zhang, 2016, Decreased expression of microRNA-320a promotes proliferation and invasion of non-small cell lung cancer cells by increasing VDAC1 expression, Oncotarget, 7, 49470, 10.18632/oncotarget.9943 · DOI
  31. Agaram, 2015, EWSR1-PBX3: a novel gene fusion in myoepithelial tumors, Genes Chromosom. Cancer, 54, 63, 10.1002/gcc.22216 · DOI
  32. Ramberg, 2016, PBX3 is a putative biomarker of aggressive prostate cancer, Int. J. Cancer, 139, 1810, 10.1002/ijc.30220 · DOI
  33. Han, 2016, MicroRNA-33a-3p suppresses cell migration and invasion by directly targeting PBX3 in human hepatocellular carcinoma, Oncotarget, 7, 42461, 10.18632/oncotarget.9886 · DOI
  34. Yuan, 2016, Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1, Hepatology, 63, 499, 10.1002/hep.27893 · DOI
  35. Sun, 2015, MiR-320a acts as a prognostic factor and Inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3, Mol. Cancer, 14, 96, 10.1186/s12943-015-0344-y · DOI

Cited by

Sorted by citations

See all 260

Metadata

Authors
Zhang, Z., Li, X., Sun, W., Yue, S., Yang, J., Li, J., Ma, B., Wang, J., Yang, X., Pu, M., Ruan, B., Zhao, G., Huang, Q., Wang, L., Tao, K., & Dou, K.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2017-07
Volume
397
Pages
33-42
ISSN
0304-3835
DOI
10.1016/j.canlet.2017.03.004
Cited by
260
References
5
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review